Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma

NCT01476410 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT01476410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01476410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
May 26, 2020
Enrollment
49 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adult lymphocyte depletion hodgkin lymphoma, adult lymphocyte predominant hodgkin lymphoma, adult mixed cellularity hodgkin lymphoma, adult nodular sclerosis hodgkin lymphoma, stage ii adult hodgkin lymphoma, stage iii adult hodgkin lymphoma, stage iv adult hodgkin lymphoma